middle.news
How Percheron’s Modular Phase II Trial Could Accelerate HMBD-002’s Cancer Fight
9:00am on Friday 30th of January, 2026 AEDT
•
Biotechnology
Read Story
How Percheron’s Modular Phase II Trial Could Accelerate HMBD-002’s Cancer Fight
9:00am on Friday 30th of January, 2026 AEDT
Key Points
Positive safety and efficacy signals from HMBD-002 phase I trial
Modular, multi-arm phase II trial design targeting several tumour types
Manufacture of new drug batch scheduled for Q2 2026 by licensor Hummingbird Bioscience
Quarter-end cash balance of $4.46 million with 3.7 quarters runway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PERCHERON THERAPEUTICS (ASX:PER)
OPEN ARTICLE